Processa Pharmaceuticals, Inc.
PCSA
$0.26
-$0.01-2.52%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -12.21% | -26.00% | -21.70% | -6.55% | 46.95% |
| Total Depreciation and Amortization | 140.00% | 175.00% | 200.00% | 250.00% | -99.75% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 20.25% | 3.34% | -19.73% | -70.78% | -93.33% |
| Change in Net Operating Assets | 395.22% | 760.73% | -187.11% | -118.57% | -150.42% |
| Cash from Operations | 3.50% | -16.93% | -49.11% | -39.46% | -31.82% |
| Capital Expenditure | 100.00% | -14.29% | -14.29% | -14.29% | -14.29% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | -14.29% | -14.29% | -14.29% | -14.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -118.92% | -147.83% | -544.44% | -- | -- |
| Issuance of Common Stock | 96.41% | 94.82% | -5.78% | 22.21% | 13.56% |
| Repurchase of Common Stock | 80.47% | 86.13% | 92.73% | 70.59% | 61.27% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 97.75% | 97.84% | -4.43% | 23.36% | 14.56% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 186.09% | 143.96% | -230.71% | -95.54% | -80.91% |